Maoto has been reported to be effective in controlling fever caused by influenza. But Maoto's effects on respiratory complications of influenza have been unknown so far. We performed a comparative study on the respiratory complication (bronchitis, pneumonia, asthma attack) rates of pediatric cases of influenza after the administration of Maoto (n = 80), Oseltamivir or Zanamivir (n = 166). Rate of using other respiratory medication at the same time is higher in Oseltamivir/Zanamivir group (64/166 = 39%) than Maoto one (12/80 = 15%) (P < 0.01). Respiratory complication rates were equal between Maoto group (34/166 = 21%) and Oseltamivir/Zanamivir one (9/80 = 11%) (P = 0.07). In the patients who had not history of bronchial asthma, respiratory complication rate is higher in Oseltamivir/Zanamivir group (19/107 = 18%) than Maoto one (4/67 = 6%) (P = 0.045). In the patients who had history of bronchial asthma and age under10, respiratory complication rate is higher in Maoto group (4/5 = 80%) than Oseltamivir/Zanamivir one (15/57 = 26%) (P = 0.047).

　　A 48-year-old man with jaundice was referred to our hospital. Endoscopic retrograde cholangiography showed primary sclerosing cholangitis. Endoscopic biliary drainage was not successful because of highly viscous bile, so we performed percutaneous trans-gallbladder drainage (PTGBD), which was able to reduce the total serum bilirubin level from 8 to 10mg/ml. Subsequently, an indwelling drainage catheter was placed in the gallbladder for 13 months. However, liver atrophy worsened with the gradual progression of hepatic failure. Twelve months later, he complained of dyspnea. Computed abdominal tomography showed that the drainage catheter had perforated the diaphragm and become exposed to the chest cavity. In spite of intensive care, the patient died of liver failure while waiting for a liver transplant. Careful attention should be paid to the possibility of this serious complication in such patients.